Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Nplate romiplostim: Phase III data

In a double-blind Phase III trial in 62 non-splenectomized chronic ITP patients, 61% 25 of 41 AMG 531

Read the full 183 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE